Zimbabwe has turned down a substantial American health deal worth $367m (£272m) spanning five years because of the United States' request for confidential information.
This move came to light after a government memo from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
An official representative has since stated that the United States was seeking health data for research and commercial purposes but refused to guarantee the resulting advantages from future treatments.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further dialogue to secure a agreement suitable to both sides so the nation's vital HIV programme can be sustained.
Broader Background
This development follows a comparable situation in Kenya, where a court suspended a similar deal with the US after legal challenges were filed about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government deals to enhance transparency and responsibility.
As per statements, Sixteen nations in Africa have to date agreed to similar agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, without any equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would provide the raw materials for medical research without any certainty that the final treatments would be accessible to our citizens if a new health crisis emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of bilateral deals were disrupting systems previously established via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This framework is designed to guarantee that when a country contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to ongoing discussions with our American counterparts on how future collaboration might be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body said it understood the official position, but suggested that negotiations need to persist considering much of the nation's HIV programmes relied on external financing.
"If technical issues arise, such as those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," it said.
This impasse underscores the ongoing debate between receiving much-needed foreign assistance and safeguarding local interests in an increasingly data-driven world.